A Prospective Randomised Trial to Determine the Effect of a Reduced Versus Standard Dose of Enzalutamide on Side Effects in Frail Patients with Prostate Cancer.

Autor: Boerrigter E; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands., Overbeek JK; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands., Benoist GE; Department of Clinical Pharmacy and Pharmacology, Deventer Hospital, Deventer, The Netherlands., Somford DM; Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Hamberg P; Department of Medical Oncology, Franciscus Gasthuis & Vlietland, Rotterdam, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands., Scholtes B; Department of Medical Oncology, Maasziekenhuis Pantein, Beugen, The Netherlands., Willemsen AECAB; Department of Internal Medicine, Tergooi Medical Center, Hilversum, The Netherlands., Buffart LM; Department of Medical BioSciences, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands., Kessels RPC; Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands; Department of Medical Psychology and Radboudumc Alzheimer Center, Radboudumc, Nijmegen, The Netherlands; Vincent van Gogh Institute for Psychiatry, Venray, The Netherlands., Mehra N; Department of Medical Oncology, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands., van Oort IM; Department of Urology, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands., van Erp NP; Department of Pharmacy, Radboudumc Research Institute for Medical Innovation, Nijmegen, The Netherlands. Electronic address: Nielka.vanErp@radboudumc.nl.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Mar 13. Date of Electronic Publication: 2024 Mar 13.

Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane.

Autor: Willemsen AECAB; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands. Electronic address: Annelieke.willemsen@radboudumc.nl., He X; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands., van Cranenbroek B; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands., de Jong PC; St. Antonius Ziekenhuis, Department of Medical Oncology, 3435CM Nieuwegein, the Netherlands., de Boer M; Maastricht University Medical Center, Division of Medical Oncology Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, 6229 HX Maastricht, the Netherlands., Joosten I; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands., Koenen HJPM; Radboud University Medical Center, Department of Laboratory Medicine, 6525 GA Nijmegen, the Netherlands., van Herpen CML; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands., Gerritsen WR; Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Oncology, 6525 GA Nijmegen, the Netherlands.

Publikováno v: International immunopharmacology [Int Immunopharmacol] 2021 Apr; Vol. 93, pp. 107404. Date of Electronic Publication: 2021 Jan 30.

Answer to Photoquiz An impressive chest X-ray….

Autor: Heidt J; Department of Intensive Care, Tergooi Hospital, Hilversum, the Netherlands., van Keulen EM, Willemsen AECAB, van Haarst JMW

Publikováno v: The Netherlands journal of medicine [Neth J Med] 2020 Dec; Vol. 78 (6), pp. 393-394.

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane.

Autor: Willemsen AECAB; Department of Medical Oncology, Radboud university medical center, route 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, P.O. Box 90153, 5200 ME, 's Hertogenbosch, The Netherlands., van Erp NP; Department of Pharmacy, Radboud university medical center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands., Jonker MA; Department for Health Evidence, Radboud university medical center, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands., de Boer M; Division of Medical Oncology Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands., Meek B; Department of Pulmonology, St. Antonius Hospital, Centre of Interstitial Lung Diseases, Nieuwegein, The Netherlands., de Jong PC; Department of Medical Oncology, St. Antonius Hospital, Nieuwegein, The Netherlands., van Moorsel C; Department of Pulmonology, St. Antonius Hospital, Centre of Interstitial Lung Diseases, Nieuwegein, The Netherlands.; Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud university medical center, route 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands., Grutters JC; Department of Pulmonology, St. Antonius Hospital, Centre of Interstitial Lung Diseases, Nieuwegein, The Netherlands.; Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands., van Herpen CML; Department of Medical Oncology, Radboud university medical center, route 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. carla.vanherpen@radboudumc.nl.

Publikováno v: Targeted oncology [Target Oncol] 2019 Aug; Vol. 14 (4), pp. 441-451.

Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane.

Autor: Willemsen AECAB; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands., de Geus-Oei LF; Department of Radiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.; Biomedical Photonic Imaging Group, MIRA Institute, University of Twente, Enschede, the Netherlands., de Boer M; Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands., Kamm Y; Department of Medical Oncology, Maasziekenhuis Pantein, Boxmeer, the Netherlands., de Jong PC; Department of Medical Oncology, St. Antonius Ziekenhuis, Utrecht, the Netherlands., Jonker MA; Department for Health Evidence, Radboud university medical center, Nijmegen, the Netherlands., Vos AH; Department of Medical Oncology, Bernhoven Ziekenhuis, Uden, the Netherlands., Grootjans W; Department of Radiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands., de Groot JWB; Isala Oncology Center, Zwolle, the Netherlands., Mulder SF; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands., Aarntzen EHJG; Department of Radiology and Nuclear Medicine, Radboud university medical center, Nijmegen, the Netherlands., Gerritsen WR; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands., van Herpen CML; Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, the Netherlands., van Erp NP; Department of Pharmacy, Radboud Institute for Health Sciences, Radboud university medical center, P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands. Nielka.vanerp@radboudumc.nl.

Publikováno v: Targeted oncology [Target Oncol] 2018 Oct; Vol. 13 (5), pp. 641-648.